Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective

Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective

Gary Benson,1 Tim Morton,2 Huw Thomas,3 Xin Ying Lee4 1Northern Ireland Haemophilia Comprehensive Care Centre and Thrombosis Unit, Belfast City Hospital, Belfast, UK; 2DRG, Bicester, UK; 3Biopharm, Novo Nordisk Ltd, Gatwick, UK; 4Biopharm Access, Novo Nordisk A/S, Søborg, DenmarkCorrespon...

Full description

Bibliographic Details
Main Authors: Benson G, Morton T, Thomas H, Lee XY
Format: Article
Language:English
Published: Dove Medical Press 2021-01-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
hemophilia a
prophylaxis
factor viii (fviii)
cost-effectiveness model
turoctocog alfa pegol
esperoct®
Online Access:https://www.dovepress.com/long-term-outcomes-of-previously-treated-adult-and-adolescent-patients-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/long-term-outcomes-of-previously-treated-adult-and-adolescent-patients-peer-reviewed-article-CEOR

Similar Items